Availability of Research Articles for the Public During Pandemic — A Case Study

Augustine Joshua Devasahayam

Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland and Labrador, Canada
augustine.joshua@mun.ca, orcid.org/0000-0001-6033-3809

Abstract

The coronavirus 2019 (COVID-19) disease has affected millions of lives, forcing most of us to stay at home and work. However, there is an immediate need to conduct research on potential drugs against COVID-19. In this article, the extent to which major publishers have provided access for the public to read research articles relevant to potential drug candidates for the COVID-19 disease are presented.

A systematic search of five electronic databases (Elsevier’s ScienceDirect, Taylor & Francis, SpringerLink, Wiley, and New England Journal of Medicine (NEJM)) was conducted on April 12–17, 2020. The total number of research articles containing terms ‘Ribavirin,’ ‘Remdesivir,’ ‘Hydroxychloroquine OR Chloroquine,’ ‘Favipiravir,’ ‘Lopinavir OR Ritonavir,’ ‘Sarilumab,’ and ‘Tocilizumab,’ available for the public to read for free were determined. In this study, there was a lack of full access to research articles related to potential drugs of COVID-19 in commercial academic databases, except for ‘Remdesivir’ and ‘Favipiravir’ from NEJM.

Keywords: Open access; scholarly communication; COVID-19; Coronavirus; pandemic
1. Introduction

The coronavirus disease 2019 (COVID-19) pandemic has impacted our lives more than we could imagine forcing most of us to stay at home and work (Amla & Amla, 2020; Ciuriak, 2020; Hamzelou, 2020; Pueyo, 2020; WHO, 2020). As we find our way through the COVID-19 crisis, some scientists are adjusting to the new routine of working from home (Burke et al., 2020). For example, clinical research not requiring patient contact is conducted remotely as per Food and Drug Administration (FDA) guidelines, while balancing the rights and safety of study participants (Padala, Jendro, & Padala, 2020). Additionally, activities such as writing grants, research articles, and peer-review are continued from home to maintain productivity while keeping researchers safe and engaged (Omary et al., 2020). At this emergent time, it is essential to recognise that the lack of access to research articles for the public to read could become a barrier to implementing evidence-based practice for healthcare professionals, policy makers, and government officials (ElSabry, 2017; Look & Marsh, 2012; Willinsky, 2003).

As pivotal as it seems, the lockdown has changed the business practices of major scientific publishers (Nadeem, 2020). In response to the COVID-19 crisis, various publishers and journals have started providing free access to research articles to encourage researchers to continue their work from home (Nadeem, 2020). As a result, the number of articles published on COVID-19 is increasing, which raises concern over the quality of research published (Peyrin-Biroulet, 2020). Nevertheless, there is an immediate need to conduct research on potential drugs and vaccine against COVID-19. One of the ways to make progress on this front is to make research articles relevant to potential drugs of COVID-19 available in the internet public domain.

The World Health Organization is now conducting a megatrial of the four most promising COVID-19 treatments (Kupferschmidt & Cohen, 2020), including Remdesivir (Cao, Deng, & Dai, 2020b), Chloroquine and hydroxychloroquine (Arnold & Buckner, 2020), and Ritonavir/lopinavir drug combinations (Cao et al., 2020a). More recently, researchers are conducting studies on Ribavirin (Khalili, Zhu, Mak, Yan, & Zhu, 2020), Favipiravir (Du & Chen, 2020), Sarilumab (Lu, Chen, & Chang, 2020), and Tocilizumab (Lu et al., 2020) in patients with COVID-19 infection. A systematic analysis of proteins encoded by severe acute respiratory syndrome coronavirus (SARS-CoV) genes using target-based virtual ligand screening has identified more than 10 drug compounds that might have anti-viral properties against COVID-19 (Wu et al., 2020). As of 12–17th
April 2020, I analysed whether research articles related to potential drug candidates of COVID-19 were available on the internet for free to read.

2. Methods

As a first step, the drugs with potential anti-viral activity against COVID-19 were selected through a literature search on PubMed. The keywords from medical subject headings (MeSH) were used to conduct the search (Drug Therapy, Drug Development, Coronavirus, COVID-19) (Table 1). After removing duplicate records, a total of 486 research articles were identified from the literature search (Table 1). Next, title and abstract screening were conducted to select articles based on the inclusion criteria (1) patients with COVID-19 disease, (2) clinical studies involving treatment of COVID-19, and (3) clinical studies with specific endpoints of recovery from COVID-19, and exclusion criterion (1) studies on other coronavirus-related diseases such as Middle East Respiratory Syndrome (MERS). From a total of six studies (Arnold & Buckner, 2020; Cao et al., 2020a,b; Du & Chen, 2020; Khalili et al., 2020; Lu et al., 2020) which were chosen for full text review, seven potential drug candidates and combinations were selected to determine how many research articles were available for the public to read for free (Table 2).

Table 1: Search history.

| Step | Search Query                                                                 | Items found |
|------|-----------------------------------------------------------------------------|-------------|
| 7    | Search (((Drug Therapy[MeSH Terms]) OR Drug Development[MeSH Terms])) AND ((Coronavirus[MeSH Terms]) OR COVID-19[Supplementary Concept]) | 486         |
| 6    | Search (Coronavirus[MeSH Terms]) OR COVID-19[Supplementary Concept]          | 12,819      |
| 5    | Search COVID-19[Supplementary Concept]                                       | 1,545       |
| 4    | Search Coronavirus[MeSH Terms]                                               | 12,598      |
| 3    | Search (Drug Therapy[MeSH Terms]) OR Drug Development[MeSH Terms]            | 1,469,432   |
| 2    | Search Drug Development[MeSH Terms]                                          | 157,950     |
| 1    | Search Drug Therapy[MeSH Terms]                                              | 1,344,112   |

MeSH: Medical Subject Headings
Table 2: Research articles available for the public to read for free as of 12–17th April 2020.

| COVID-19 candidate treatments | Elsevier’s ScienceDirect | Taylor & Francis Online | SpringerLink | Wiley Online Library | NEJM |
|------------------------------|--------------------------|--------------------------|--------------|---------------------|------|
| Search Query                 |                          |                          |              |                     |      |
| “Ribavirin” (Khalili et al., 2020) | Total=7,547 | Total=2,321 | Total=7,869 | Total=10,818 | Total=93 |
|                              | Open access=1,032        |                          |              |                     |      |
|                              | Open archive=420         |                          |              |                     |      |
|                              | Available=1,130          | Available=443           | Available=1,746 | Available in first 2,000 articles listed=818** | Available=86 |
| “Remdesivir” (Cao et al., 2020b) | Total=56               | Total=16                | Total=38     | Total=65            | Total=6 |
|                              | Open access=8            |                          |              |                     |      |
|                              | Open archive=0           |                          |              |                     |      |
|                              | Available=51             | Available=12            | Available=36 | Available=59        | Available=6 |
|                              | Total=19,099             | Total=6,166             | Total=15,877 | Total=18,644        | Total=131 |
|                              | Open access=2,372        |                          |              |                     |      |
|                              | Open archive=1,258       |                          |              |                     |      |
|                              | Available=858*           | Available=1,213         | Available=5,004 | Available in first 2,000 articles listed=771** | Available=56 |
| “Hydroxychloroquine” OR “Chloroquine” (Arnold & Buckner, 2020) | Total=169               | Total=75                | Total=131    | Total=84            | Total=5 |
|                              | Open access=38           |                          |              |                     |      |
|                              | Open archive=5           |                          |              |                     |      |
|                              | Available=66             | Available=32            | Available=73 | Available=61        | Available=5 |
|                              | Total=4,460              | Total=2,916             | Total=7,202  | Total=5,981         | Total=70 |
|                              | Open access=594          |                          |              |                     |      |
|                              | Open archive=218         |                          |              |                     |      |
|                              | Available=948            | Available=216           | Available=1,661 | Available in first 2,000 articles listed=1,093** | Available=69 |
| “Lopinavir” OR “Ritonavir” (Cao et al., 2020a) | Total=46                | Total=100               | Total=199    | Total=92            | Total=0 |
|                              | Open access=4            |                          |              |                     |      |
|                              | Open archive=2           |                          |              |                     |      |
|                              | Available=12             | Available=18            | Available=82 | Available=70        | Available=0 |
|                              | Total=1,420              | Total=1,405             | Total=4,015  | Total=2,049         | Total=15 |
|                              | Open access=242          |                          |              |                     |      |
|                              | Open archive=75          |                          |              |                     |      |
|                              | Available=349            | Available=162           | Available=1,322 | Available in first 2,000 articles listed=1,222** | Available=13 |
| “Sarilumab” (Lu et al., 2020) | Total=46                | Total=100               | Total=199    | Total=92            | Total=0 |
|                              | Open access=4            |                          |              |                     |      |
|                              | Open archive=2           |                          |              |                     |      |
|                              | Available=12             | Available=18            | Available=82 | Available=70        | Available=0 |
| “Tocilizumab” (Lu et al., 2020) | Total=1,420              | Total=1,405             | Total=4,015  | Total=2,049         | Total=15 |
|                              | Open access=242          |                          |              |                     |      |
|                              | Open archive=75          |                          |              |                     |      |
|                              | Available=349            | Available=162           | Available=1,322 | Available in first 2,000 articles listed=1,222** | Available=13 |

*Elsevier’s ScienceDirect database provided a maximum of 6,000 research articles per search;
**Wiley Online Library database provided a maximum of 2,000 articles per search; NEJM: New England Journal of Medicine.
The availability of research articles containing search terms of seven potential COVID-19 drug candidates and combinations (Table 2) for the public to read for free from the internet as of 12–17th April 2020 were determined from online databases of four major publishers (Elsevier’s ScienceDirect, Taylor & Francis, SpringerLink, and Wiley) (see Screen-capture A1.1–A4.7) (Larivière, Haustein, & Mongeon, 2015; Rolnik, Binfield, & Graves, 2008). A similar search was conducted on the online database of the New England Journal of Medicine (NEJM) as several drug studies on human subjects with lower statistical errors related to the documentation, presentation, and interpretation of findings have been published in NEJM (see Screen-capture A5.1–A5.7) (Strasak, Zaman, Marinell, Pfeiffer, & Ulmer, 2007). The lack of access to research articles that were locked behind website paywalls was determined separately for all five databases (see Screen-capture B6.1).

3. Results

The maximum number of research articles accessible from the journals in Elsevier’s ScienceDirect database is 6,000 per search query (from a total of 60 webpages with each containing 100 research items). The terms ‘Ribavirin’ and ‘Hydroxychloroquine OR Chloroquine’ returned more than 6,000 research articles each during the search (Table 2). The number of research articles that were available for free in the first 6,000 articles accessible from Elsevier’s ScienceDirect database were counted and reported (Table 2). The total number of research articles containing search terms of potential COVID-19 drug candidates such as Ribavirin, Remdesivir, Hydroxychloroquine OR Chloroquine, Favipiravir, Lopinavir OR Ritonavir, Sarilumab, and Tocilizumab, available for the public to read for free on 17th April 2020 in Elsevier’s ScienceDirect database was 1,130, 51, 858, 66, 948, 12, and 349 respectively (Table 2).

The total number of research articles containing search terms listed consecutively as above (on Table 2) available for the public to read for free on 12th April 2020 in Taylor & Francis Online database was 443, 12, 1,213, 32, 216, 18, and 162 respectively (Table 2). The total number of research articles containing search terms listed consecutively on Table 2 available for the public to read for free on 12th April 2020 in SpringerLink database was 1,746, 36, 5,004, 73, 1,661, 82, and 1,322 respectively (Table 2).

The maximum number of research articles accessible from the journals in Wiley Online Library is 2,000 per search query (from a total of 100
webpages with each containing 20 research items). The terms ‘Ribavirin,’ ‘Hydroxychloroquine OR Chloroquine,’ ‘Lopinavir OR Ritonavir,’ and ‘Tocilizumab’ returned more than 2,000 research articles each during the search (Table 2). The number of research articles that were available for free in the first 2,000 articles accessible from Wiley Online Library database were counted and reported (Table 2). The total number of research articles containing search terms listed consecutively on Table 2 available for the public to read for free on 12th April 2020 from the journals listed in Wiley Online Library was 818, 59, 771, 61, 1,093, 70, and 1,222 respectively (Table 2).

The research articles containing search terms of potential COVID-19 drug candidates such as Ribavirin, Remdesivir, Hydroxychloroquine OR Chloroquine, Favipiravir, Lopinavir OR Ritonavir, and Tocilizumab, available for the public to read for free on 12th April 2020 in NEJM database was 86, 6, 56, 5, 69, and 13 (Table 2). The term ‘Sarilumab’ did not return search results in the NEJM database. In this study, there was a lack of full access to research articles relevant to potential drugs of COVID-19 (Figure 1).

4. Discussion and Conclusions

In this study, the availability of research articles relevant to potential drugs of COVID-19 disease for the public to read for free was determined. At the time of this study when the pandemic was increasing, many research articles containing terms ‘Ribavirin,’ ‘Remdesivir,’ ‘Hydroxychloroquine OR Chloroquine,’ ‘Favipiravir,’ ‘Lopinavir OR Ritonavir,’ ‘Sarilumab,’ and ‘Tocilizumab’ from online databases of Elsevier’s ScienceDirect, Taylor & Francis, SpringerLink, and Wiley were not available for the public to read for free (Table 2). For search terms ‘Remdesivir’ (n=6) and ‘Favipiravir’ (n=5), the online database of NEJM provided all available articles to read for free (Table 2).

Since the start of this pandemic, many academic publishers promised to make research articles relevant to COVID-19 virus free to read from the internet. For example, Elsevier’s ScienceDirect database returned 21,000+ articles free to read following the search using “COVID-19” OR Coronavirus OR “Corona virus” OR “2019-nCoV” OR “SARS-CoV” OR “MERS-CoV” OR “Severe Acute Respiratory Syndrome” OR “Middle East Respiratory Syndrome”
terms. The NEJM has provided all journal content related to COVID-19 pandemic free to read from the internet. However, in this case study, it was found that articles relevant to potential drugs for COVID-19 infection were not entirely free to read (Figure 1). At this time of crisis, it is not only essential to provide free access to research articles related to the search terms ‘COVID-19’ or ‘SARS-CoV’ but also the allied content necessary to conduct research and develop health policies.

Since the turn of this century, there were massive changes in scholarly communication due to digitalisation and therefore, scientific material was easily
accessible from the internet (Baffy et al., 2020). As a consequence, free access to research articles through the internet has increased the scientific output from developing countries (Mueller-Langer, Scheufen, & Waelbroeck, 2020). This has raised a serious concern about the quality of research articles published through online open access journal systems (Bohannon, 2013). It is indeed necessary to have quality checking measures in place through open science initiatives to improve the standard of research output (Walther & van den Bosch, 2012). Although there are concerns over the quality of research articles published rapidly during this pandemic, we should realize that scientific progress depends on real time response to the pandemic through research conducted both in laboratory and at home (Kaplan, 2014). For example, some researchers might be more effective writing their manuscripts at home (Bažant, 1993). It is therefore necessary to make sure that researchers have free and easy access to academic databases at this emergent time. As stated by Zdenek P. Bažant (Bažant, 1993), “the only thing that matters in research is what is achieved.” To overcome the COVID-19 emergency, it is essential for the publishers to provide free access to research articles, facilitate data sharing, and support the position of the World Health Organization on Open Science (Moorthy, Restrepo, Preziosi, & Swaminathand, 2020).

**Availability of research data:** The full video screen captures of the performed searches are available from the LIBER Quarterly Dataverse at [https://doi.org/10.7910/DVN/IZ3VAU](https://doi.org/10.7910/DVN/IZ3VAU).

**References**

Amla, K., & Amla, T. (2020). *The impact of public safety measures on the spread of COVID-19 in the United States assessed by causal model-based projections of the pandemic.* arXiv preprint arXiv:2004.03200. Retrieved April 29, 2020, from [https://arxiv.org/abs/2004.03200](https://arxiv.org/abs/2004.03200).

Arnold, S. L., & Buckner, F. (2020). Hydroxychloroquine for treatment of SARS-CoV-2 infection? Improving our confidence in a model-based approach to dose selection. *Clinical and Transnational Science.* Accepted author manuscript. [https://doi.org/10.1111/cts.12797](https://doi.org/10.1111/cts.12797).

Baffy, G., Burns, M. M., Hoffmann, B., Ramani, S., Sabharwal, S., Borus, J. F., … Ingelfinger, J. R. (2020). Scientific authors in a changing world of scholarly communication: What does the future hold? *The American Journal of Medicine, 133*(1), 26–31. [https://doi.org/10.1016/j.amjmed.2019.07.028](https://doi.org/10.1016/j.amjmed.2019.07.028).
Bažant, Z. P. (1993). Public Funding of University Research and Graduate Programs. *ASEE Centennial Annual Conference Proceedings*, 341–345. Retrieved April 29, 2020, from http://www.civil.northwestern.edu/people/bazant/PDFs/Papers/G2.pdf.

Bohannon, J. (2013). Who’s afraid of peer review? *Science*, 342(6154), 60–65. https://doi.org/10.1126/science.342.6154.60.

Burke, J. F., Chan, A. K., Mummaneni, V., Chou, D., Lobo, E. P., Berger, M. S., … Mummaneni, P. V. (2020, April 3). The Coronavirus Disease 2019 Global Pandemic: A Neurosurgical Treatment Algorithm. *Neurosurgery, nyaa116*, n.p. https://doi.org/10.1093/neuros/nyaa116.

Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., … Wang, C. (2020a, March 18). A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19. *New England Journal of Medicine*. https://doi.org/10.1056/NEJMoa2001282.

Cao, Y. C., Deng, Q. X., & Dai, S. X. (2020b). Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. *Travel Medicine and Infectious Disease*, 101647 (in press). https://doi.org/10.1016/j.tmaid.2020.101647.

Ciuriak, D. (2020). The policy response to the Coronavirus pandemic: Recommendations for Canada. Centre for International Governance Innovation. Retrieved April 29, 2020, from https://www.cigionline.org/articles/policy-response-coronavirus-pandemic-recommendations-canada.

Du, Y. X., & Chen, X. P. (2020). Favipiravir: Pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. *Clinical Pharmacology & Therapeutics*, Early view. https://doi.org/10.1002/cpt.1844.

ElSabry, E. (2017). Who needs access to research? Exploring the societal impact of open access. *Revue française des sciences de l’information et de la communication [En ligne]*, 11, n.p. https://doi.org/10.4000/rfsic.3271.

Hamzelou, J. (2020). World in lockdown. *NewScientist* 245(3275), 7. https://doi.org/10.1016/S0262-4079(20)30611-4.

Kaplan, K. (2014). Telecommuting: No place like home. *Nature*, 506(7486), 121–123. https://doi.org/10.1038/nj7486-121a.

Khalili, J. S., Zhu, H., Mak, A., Yan, Y., & Zhu, Y. (2020, March 30). Novel coronavirus treatment with ribavirin: Groundwork for evaluation concerning COVID-19. *Journal of Medical Virology*, Early view. https://doi.org/10.1002/jmv.25798.

Kupferschmidt, K., & Cohen, J. (2020, March 22). WHO launches global megatrial of the four most promising coronavirus treatments. *Science News* [blog post]. https://doi.org/doi:10.1126/science.abb8497.

Larivière, V., Haustein, S., & Mongeon, P. (2015). Big publishers, bigger profits: How the scholarly community lost the control of its journals. *MediaTropes*, 5(2), 102–110.
Look, H., & Marsh, K. (2012). Benefits of open access to scholarly research to the public sector: A research report to JISC from Rightscom Ltd and Matrix Evidence Ltd. London: Rightscom Limited. Retrieved April 29, 2020, from https://wiki.lib.sun.ac.za/images/e/e3/Report-to-oauk-benefits-of-open-access-public-sector.pdf.

Lu, C. C., Chen, M. Y., & Chang, Y. L. (2020, April 1). Potential therapeutic agents against COVID-19: What we know so far. Journal of the Chinese Medical Association. Volume latest articles. https://doi.org/10.1097/jcma.0000000000000318.

Moorthy, V., Restrepo, A. M. H., Preziosi, M.-P., & Swaminathand, S. (2020). Data sharing during the novel coronavirus public health emergency of international concern. Bulletin of the World Health Organization, 98(3), 150. https://doi.org/10.2471/BLT.20.251561.

Mueller-Langer, F., Scheufen, M., & Waelbroeck, P. (2020). Does online access promote research in developing countries? Empirical evidence from article-level data. Research Policy, 49(2), 103886, 1–22. https://doi.org/10.1016/j.respol.2019.103886.

Nadeem, S. (2020). Coronavirus COVID-19: Available free literature provided by various companies, journals and organizations around the world. Journal of Ongoing Chemical Research, 5(1), 7–13. https://doi.org/10.5281/zenodo.3722904.

Omary, M. B., Eswaraka, J., Kimball, S. D., Moghe, P. V., Panettieri Jr., R. A., & Scotto, K. W. (2020). The COVID-19 pandemic and research shutdown: Staying safe and productive. The Journal of clinical investigation, 130(6), n.p.. https://doi.org/10.1172/JCI138646.

Padala, P. R., Jendro, A. M., & Padala, K. P. (2020). Conducting clinical research during the COVID-19 Pandemic: Investigator and participant perspectives. JMIR Public Health Surveillance, 6(2), e18887, 1–4. https://doi.org/10.2196/18887.

Peyrin-Biroulet, L. (2020). Will the quality of research remain the same during the COVID-19 pandemic? Clinical Gastroenterology and Hepatology. Article in press. https://doi.org/10.1016/j.cgh.2020.03.054.

Pueyo, T. (2020). Coronavirus: Why you must act now. Politicians, community leaders and business leaders: What should you do and when. Medium. Retrieved April 29, 2020, from https://medium.com/@tomaspueyo/coronavirus-act-today-or-people-will-die-f4d3d9cd99ca.

Rolnik, Z., Binfield, P., & Graves, T. (2008). Publishing 101: The basics of academic publishing. The Serials Librarian, 54(1–2), 37–42. https://doi.org/10.1080/03615260801973414.
Strasak, A. M., Zaman, Q., Marinell, G., Pfeiffer, K. P., & Ulmer, H. (2007). The use of statistics in medical research. *The American Statistician, 61*(1), 47–55. https://doi.org/10.1198/000313007X170242.

Walther, A., & van den Bosch, J. (2012). FOSE: A framework for open science evaluation. *Frontiers in Computational Neuroscience, 6*(32), 1–8. https://doi.org/10.3389/fncom.2012.00032.

WHO (World Health Organization). (2020). Coronavirus disease 2019 (COVID-19): Situation report—72. Retrieved April 29, 2020, from https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200401-sitrep-72-covid-19.pdf?sfvrsn=3dd8971b_2.

Willinsky, J. (2003). Policymakers’ online use of academic research. *Education Policy Analysis Archives, 11*(2), 1–23. https://doi.org/10.14507/epaa.v11n2.2003.

Wu, C., Liu, Y., Yang, Y., Zhang, P., Zhong, W., Wang, Y., … Li, H. (2020, February 27). Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. *Acta Pharmaceutica Sinica B*. In press. https://doi.org/10.1016/j.apsb.2020.02.008.

Note

1 All screen-captures are available for downloading from the LIBER Quarterly Dataverse at https://doi.org/10.7910/DVN/1Z3VAU.